Spontaneous recovery of bone mass after cure of endogenous hypercortisolism

Pituitary

Volumn 15, Issue 2, 2012, Pages 193-201

  Randazzo, Maria Elena ^a   Grossrubatscher, Erika ^a   Ciaramella, Paolo Dalino ^a   Vanzulli, Angelo ^a   Loli, Paola ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Bisphosphonates; Bone; Cushing's disease; Hypercortisolism; Osteopenia; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; CORTISONE ACETATE; DEXAMETHASONE;

ADOLESCENT; ADULT; ARTICLE; BODY DENSITY; BODY MASS; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CLINICAL ARTICLE; CUSHING DISEASE; CUSHING SYNDROME; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECTOPIC CORTICOTROPIN PRODUCTION; FEMALE; FEMUR; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCORTISOLISM; HYPOGONADISM; LONG TERM CARE; LOW DRUG DOSE; LUMBAR SPINE; MALE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TRANSSPHENOIDAL SURGERY;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BODY MASS INDEX; BONE AND BONES; BONE DISEASES, METABOLIC; CUSHING SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PITUITARY ACTH HYPERSECRETION; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; YOUNG ADULT;

EID: 84861459385     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0306-3     Document Type: Article

References (38)

1. Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing's syndrome and bone. Pituitary 7:249-252 (Pubitemid 43115860)
2. Kaltsas G, Manetti L, Grossman AB (2002) Osteoporosis in Cushing's syndrome. Front Horm Res 30:60-72
3. Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11:79-85 (Pubitemid 30164202)
4. Osella G, Reimondo G, Peretti P, Ali A, Paccotti P, Angeli A, Terzolo M (2001) The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J Clin Endocrinol Metab 86:604-607 (Pubitemid 32207466)
5. Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U, Mosekilde L (2002) Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol 146:51-56 (Pubitemid 34126419)
6. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab 88:5593-5602 (Pubitemid 38033020)
7. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229 (Pubitemid 37409336)
8. Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D, Iori N, Bilezikian JP, Veldhuis JD, Giustina A (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152:199-205 (Pubitemid 40309565)
9. Canalis E (1996) Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:3441-3447 (Pubitemid 26339895)
10. Reid IR (2000) Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 14:279-298
11. Giustina A, Wehrenberg WB (1992) The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance. Trends Endocrinol Metab 3:306-311
12. Delany AM, Durant D, Canalis E (2001) Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781-1789 (Pubitemid 32939308)
13. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M (2004) Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 15:855-861 (Pubitemid 39506451)
14. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: A prospective, long-Term study. Eur J Endocrinol 154:109-118 (Pubitemid 43250744)
15. Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 80:2859-2865
16. Catargi B, Tabarin A, Basse-Cathalinat B, Ducassou D, Roger P (1996) Development of bone mineral density after cure of Cushing's syndrome]. Ann Endocrinol (Paris) 57:203-208 (Pubitemid 26261241)
17. Kawamata A, Iihara M, Okamoto T, Obara T (2008) Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World J Surg 32:890-896
18. Manning PJ, Evans MC, Reid IR (1992) Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 36:229-234
19. Luisetto G, Zangari M, Camozzi V, Boscaro M, Sonino N, Fallo F (2001) Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing's syndrome. Osteoporos Int 12:956-960 (Pubitemid 34001010)
20. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996 (Pubitemid 26200050)
21. Stazi AV, Manno V, Torre M (2009) Osteoporosi: cause, prevenzione, terapie e dati epidemiologici. Notiziario dell'istituto superiore di sanitá 22(12): 3-8. http://www.iss.it/binary/cont/NotiziarioDicembre- 2009.pdf. Accessed 27 December 2010
22. World Health Organization Scientific Group on the Prevention and Management of Osteoporosis (2000) Prevention and management of osteoporosis: report of a WHO scientific group. WHO technical report series n. 921
23. Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL (1996) Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 20:1027-1032 (Pubitemid 26366457)
24. Greco EA, Fornari R, Rossi F, Santiemma V, Prossomariti G, Annoscia C, Aversa A, Brama M, Marini M, Donini LM, Spera G, Lenzi A, Lubrano C, Migliaccio S (2010) Is obesity protective for osteoporosiš Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract 64:817-820
25. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: A meta-Analysis. Osteoporos Int 16:1330-1338 (Pubitemid 41532085)
26. Shapses SA, Riedt CS (2006) Bone, body weight, and weight reduction: what are the concernš J Nutr 136:1453-1456 (Pubitemid 43765343)
27. Tauchmanova L, Pivonello R, De Martino MC, Rusciano A, De Leo M, Ruosi C, Mainolfi C, Lombardi G, Salvatore M, Colao A (2007) Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol 157:359-366 (Pubitemid 47603542)
28. Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, Norman MR, Monson JP (1994) The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 41:639-648 (Pubitemid 24336867)
29. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29: 535-559
30. Faggiano A, Pivonello R, Filippella M, Di Somma C, Orio F Jr., Lombard G, Colao A (2001) Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary 4:153-161
31. Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, Pileri M, Modoni S, Di Giorgio A, Liuzzi A, Minisola S, Cammisa M, Trischitta V, Scillitani A (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 83:1863-1867 (Pubitemid 28496307)
32. Tauchmanova L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779-1784
33. Compston J (2004) US and UK guidelines for glucocorticoidinduced osteoporosis: similarities and differences. Curr Rheumatol Rep 6:66-69
34. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387 (Pubitemid 27328368)
35. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299 (Pubitemid 28366417)
36. Tauchmanova L, Guerra E, Pivonello R, De Martino MC, De Leo M, Caggiano F, Lombardi G, Colao A (2009) Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. J Endocrinol Invest 32:390-394
37. Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS, Merola B, Salvatore M, Lombardi G (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 48:655-662 (Pubitemid 28253004)
38. Plotkin LI, Bivi N, Bellido T (2010) A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone